Ajanta Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Profit Before Tax
1,189.00
1,113.00
745.00
909.00
900.00
663.00
Adjustment
112.00
83.00
131.00
91.00
115.00
70.00
Changes In working Capital
178.00
-99.00
66.00
-200.00
-208.00
-123.00
Cash Flow after changes in Working Capital
1,480.00
1,097.00
943.00
800.00
806.00
611.00
Cash Flow from Operating Activities
1,157.00
785.00
792.00
561.00
576.00
456.00
Cash Flow from Investing Activities
-376.00
65.00
-559.00
-74.00
-282.00
-224.00
Cash Flow from Financing Activities
-733.00
-1,051.00
-108.00
-459.00
-318.00
-128.00
Net Cash Inflow / Outflow
47.00
-200.00
124.00
27.00
-24.00
103.00
Opening Cash & Cash Equivalents
129.00
329.00
206.00
177.00
202.00
95.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
176.00
129.00
330.00
205.00
177.00
198.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Ajanta Pharma
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
1189.16
1131.14
58.00
5.13%
Adjustment
112.11
727.89
-615.00
-84.60%
Changes In working Capital
178.93
-176.46
354.00
201.40%
Cash Flow after changes in Working Capital
1480.2
1682.57
-202.00
-12.03%
Cash Flow from Operating Activities
1157.23
1321.32
-164.00
-12.42%
Cash Flow from Investing Activities
-376.52
-869.5
493.00
56.70%
Cash Flow from Financing Activities
-733.41
-282.98
-451.00
-159.17%
Net Cash Inflow / Outflow
47.3
168.84
-121.00
-71.99%
Opening Cash & Cash Equivalents
129.49
755.79
-626.00
-82.87%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
176.79
924.63
-748.00
-80.88%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 47.40% vs -0.89% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
1,157.23
785.07
47.40%






